QCG
TGTX icon

Quadrant Capital Group’s TG Therapeutics TGTX Stock Holding History

Quadrant Capital Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,388
Closed -$46.1K – 2454
2026
Q1 		$46.1K Sell
1,388
-89
-6% -$2.65K ﹤0.01% 1734
2025
Q4 		$44K Sell
1,477
-114
-7% -$3.72K ﹤0.01% 1732
2025
Q3 		$57.5K Buy
+1,591
New +$52.4K ﹤0.01% 1629
2025
Q2 		– Sell
-11,927
Closed -$470K – 2500
2025
Q1 		$470K Buy
11,927
+10,241
+607% +$345K 0.02% 783
2024
Q4 		$50.7K Buy
1,686
+975
+137% +$28K ﹤0.01% 1411
2024
Q3 		$16.6K Buy
+711
New +$15.5K ﹤0.01% 1972
2021
Q4 		– Sell
-11
Closed – – 2693
2021
Q3 		$0 Buy
11
+8
+267% +$248 ﹤0.01% 2648
2021
Q2 		$0 Buy
+3
New +$118 ﹤0.01% 2558
2016
Q2 		– Sell
-598
Closed -$5K – 2075
2016
Q1 		$5K Buy
+598
New +$5.23K ﹤0.01% 1178

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Quadrant Capital Group's TGTX Position: Q2 2026 in Review

Quadrant Capital Group sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 1,388 shares — an estimated $46.1K sold.

Quadrant Capital Group first reported a position in TGTX in Q1 2016 and held it in 9 quarters. The position peaked at $470K in Q1 2025. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Quadrant Capital Group reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 1,388 TG Therapeutics shares in Q2 2026, an estimated $46.1K.
  • Quadrant Capital Group first reported a position in TG Therapeutics in Q1 2016 and held it in 9 quarters.
  • Quadrant Capital Group's TG Therapeutics position peaked at $470K in Q1 2025.
  • 428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.